Get started
SHLF buying opportunity?SHLF made a ridiculous breakout at the beginning of this week. Since then has come down pretty hard as well. So looking for potential support and buying opportunities. After the recent bottom formation the break out occurred after mounting the 3.80-3.93 resistance area. This could now provide support. Furthermore, if SHLF was to retest this level it would also touch on the upward trendline (blue) that has been established since the bottom, providing further support. And finally also note the gap
S
by duco1
Norwegian airlines, Company evaluation and long-entry strategy ABOUT - Low cost airline company that offer nice and comfortable, cheap flights to (especially) Europe and Worldwide destinations. - Adapting Bitcoin as accepted payment from August. MANAGEMENT - One of two major airlines in Norway. - Been taking a substantial beating during the Coronavirus crisis, risking bankruptcy. - Change of management last year. Previous management took a lot of irresponsible expansion risks. Current management is more responsible and have a lot of experience.
OSL:NASLong
by Navigating_Shifting_Landscapes
15
BGBIO - an intelligent bet on covidBGBIO is a biotech company with focus on cancer treatment. Like most biotech it is extremely volatile for news, but often fluctuate between key buy and sell zones when no news are evident. BGBIO is presenting news on their cancer treatment 25th of june. They are currently first in line to do a free test in ACCORD - the British rushed testing setup for COVID-19 Before news I expect the share to keep bouncing back and forth between the buy zone (established from a large public offering at 37,5
BLong
by ssholtskog
BerGenBio $BGBIO upgraded target price to 86 NOK from ArcticSecQuote: "Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly. Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86. Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely." Source: www.research-t
BLong
by savepiginvest